[1]刘 丽,卲天朋,杨 涛,等.经动脉灌注rAd- p53联合TAE治疗中晚期肝癌的疗效观察[J].介入放射学杂志,2016,(03):210-213.
　LIU Li,SHAO Tian- peng,YANG Tao,et al.Intra- arterial infusion of rAd- p53 combined with transcatheter arterial embolization for middle- late stage hepatocellular carcinoma： observation of its therapeutic efficacy[J].journal interventional radiology,2016,(03):210-213.
点击复制

经动脉灌注rAd- p53联合TAE治疗中晚期肝癌的疗效观察 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年03期
页码:
210-213
栏目:
肿瘤介入
出版日期:
2016-03-25

文章信息/Info

Title:
Intra- arterial infusion of rAd- p53 combined with transcatheter arterial embolization for middle- late stage hepatocellular carcinoma： observation of its therapeutic efficacy
作者:
刘 丽;  卲天朋;  杨 涛;  曹建民;  卢光明;  许 健
Author(s):
LIU Li;  SHAO Tian- peng;  YANG Tao;  CAO Jian- min;  LU Guang- ming;  XU Jian
Department of Medical Imaging， School of Medicine， Nanjing University， General Hospital of Nanjing Military Region， Nanjing， Jiangsu Province 210002， China
关键词:
【关键词】 重组人p53腺病毒注射液;  中晚期肝癌;  经动脉栓塞术;  疗效评估
文献标志码:
A
摘要:
【摘要】 目的 探讨经动脉灌注重组人p53腺病毒注射液联合碘化油栓塞治疗中晚期肝癌的安全性及有效性。方法 回顾性分析2012年5月至2015年6月采用经肿瘤供血动脉灌注重组人p53腺病毒注射液联合碘化油栓塞治疗的31例中晚期原发性肝癌患者的临床资料。所有入组患者均为无法行外科手术治疗的中晚期肝癌患者。患者介入术程顺利，术后采用改良实体瘤评价标准（mRECIST）评价临床疗效。采用SPSS 18.0软件进行统计分析。结果 31例患者共进行76次（平均每例2.4次）介入治疗。随访3～36个月，术后3、6、12个月完全缓解率（CR）均为0，部分缓解率分别为58.1%、38.7%、29%，总有效率分别为58.1%、38.7%、29%；6个月、1年及2年的总生存率分别为77.4%、58.1%、19.3%；6个月、1年及2年的无进展生存率分别为38.7%、25.8%、12.9%。全组患者均未见急性肝衰竭、肝脓肿、肺栓塞等严重并发症，术后87.1%患者出现发热。结论 采用经动脉灌注重组人p53腺病毒注射液联合TAE治疗中晚期肝癌具有良好的安全性和有效性，为中晚期肝癌提供了一种新的治疗选择。

参考文献/References:

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61: 69- 90.
［2］ Pinter M, Hucke F, Graziadei I, et al. Advanced- stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib［J］. Radiology, 2012, 263: 590- 599.
［3］ Choi J, Shim JH, Shin YM, et al. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma［J］. J Hepatol, 2014, 60: 1212- 1218.
［4］ Boerman OC, Koppe MJ, Postema EJ, et al. Radionuclide therapy of cancer with radiolabeled antibodies［J］. Anticancer Agents Med Chem, 2007, 7: 335- 343.
［5］ 刘会春． 中国原发性肝癌治疗指南解读［J］． 肝胆外科杂志，2013， 21： 12- 14．
［6］ Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells［J］. World J Gastroenterol, 2009, 15: 4582- 4586.
［7］ Hsia CC, Nakashima Y, Thorgeirsson SS, et al. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma［J］. Oncol Rep, 2000, 7: 353- 356.
［8］ Jeng KS, Sheen IS, Chen BF, et al. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection?［J］. Arch Surg, 2000, 135: 1329- 1333.
［9］ Chen GG, Merchant JL, Lai PB, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP- 89［J］. Am J Pathol, 2003, 162: 1823- 1829.
［10］ Qin LX, Tang ZY, Ma ZC, et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection［J］. World J Gastroenterol, 2002, 8: 459- 463.
［11］ Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?［J］. World J Gastroenterol, 2003, 9: 1202- 1207.
［12］ Peng Z. Current status of gendicine in China: recombinant human Ad- p53 agent for treatment of cancers［J］. Hum Gene Ther, 2005, 16: 1016- 1027.
［13］ Tu K, Zheng X, Zhou Z, et al. Recombinant human adenovirus- p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53- Fbxw7 pathway, which controls c- Myc and cyclin E［J］. PLoS One, 2013, 8: e68574.
［14］ Li X, Xiao S, Li Y, et al. Clinical antiangiogenic effect of recombinant adenovirus- p53 combined with hyperthermia for advanced cancer［J］. Chin J Cancer Res, 2013, 25: 749- 755.
［15］ Shen A, Liu S, Yu W, et al. P53 gene therapy- based transarterial chemoembolization for unresectable hepatocelluar carcinoma: a prospective cohort study［J］. J Gastroenterol Hepatol, 2015, 30: 1651- 1656.
［16］ Chen GX, Zhang S, He XH, et al. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives［J］. Onco Targets Ther, 2014, 7: 1901- 1909.
［17］ Guan YS, Liu Y, He Q, et al. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one- year follow- up［J］. World J Gastroenterol, 2011, 17: 2143- 2149.

相似文献/References:

[1]孔铭新,赵廷常,郝刚,等.介入治疗肝破裂三例[J].介入放射学杂志,1999,(02):21.
[2]王永彬,张余胜.农村基层介入性治疗疗效不佳的因素分析[J].介入放射学杂志,1992,(01):30.
[3]贾雨辰.肝癌介入治疗的近展[J].介入放射学杂志,1995,(02):112.
[4]贾雨辰.肝癌介入治疗的一些基本原则[J].介入放射学杂志,1995,(03):125.
[5]贾雨辰,田建明,王振堂,等.为进一步提高肝癌介入治疗的效果而努力[J].介入放射学杂志,1996,(01):1.
[6]顾苏滨,周群慧.提高间接法门脉造影质量的DSA技术措施[J].介入放射学杂志,1996,(01):41.
[7]唐军,周宝康.肝动脉内药物灌注与栓塞化疗对中晚期肝癌的疗效对比——附80例分析[J].介入放射学杂志,1996,(01):49.
[8]王执民.中晚期原发性肝癌DSA表现的分型及临床意义[J].介入放射学杂志,1996,(01):36.
[9]高中度,茅爱武,王月芹,等.白介素-2联合生脉注射液治疗肝癌栓塞化疗后临床观察[J].介入放射学杂志,2000,(01):43.
[10]毛剑婷,黄旭芳,纪建松,等.奥马哈系统在TACE治疗中晚期肝癌患者护理中的应用效果 [J].介入放射学杂志,2017,(07):660.
　MAO Jianting,HUANG Xufang,JI Jiansong,et al.The application of Omaha system in the clinical nursing for patients with advanced hepatocellular carcinoma treated with TACE[J].journal interventional radiology,2017,(03):660.

备注/Memo

备注/Memo:
（收稿日期：２０１5-０7-23）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-03-22